相关实验视频

Updated: May 6, 2026

Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents

Meal Duration as a Measure of Orofacial Nociceptive Responses in Rodents

Published on: January 10, 2014

慢性普拉姆林提德通过减少雄性大鼠的食大小来减少食

Katherine A Kern¹, Adrianne M DiBrog¹, Kiran Kaur¹

¹Exercise and Nutrition Sciences, School of Public Health and Health Professions, University at Buffalo, State University of New York, Buffalo, NY 14214, USA.

|March 17, 2024

概括

普拉姆林提德是一种氨基林类似物,主要通过减少食大小而不是食频率来减少大鼠的食物摄入量. 这一发现提供了关于这种糖尿病药物如何促进体重管理的见解.

科学领域:

内分泌学在内分泌学.
神经科学是一个神经科学.
行为科学行为科学

背景情况:

胰腺激素氨酸通过增强腹感来抑制食.
普拉姆林提德是FDA批准的用于糖尿病的氨酸类似物,也会诱导低食症.
普拉姆林提德诱导的低食症的确切行为机制尚不清楚.

研究的目的:

为了研究系统性普拉姆林提德 (pramlintide) 管理抑制大鼠食的行为机制.
为了确定pramlintide是否通过影响食大小,食次数或食速度来降低能量摄入量.

主要方法:

雄性大鼠每天两次在一周内内内注射普拉姆林提德或载体.
监测了的摄入量,饮食模式 (大小,持续时间,数量,速度) 和体重.
进行了统计分析,以比较治疗组.

主要成果:

普拉姆林提德显著降低了整体食摄入量.
减少摄入量的主要机制是显著抑制餐食大小.
食时间也缩短了几天,而食数量和食速度的变化很小.
在研究期间,Pramlintide的使用导致体重增加减少.

结论:

普拉姆林提德抑制了大鼠的食物摄入,主要是通过减少食大小,类似于氨基林.
这些发现阐明了普拉姆林提德低垂体效应背后的行为机制.
这提供了关于pramlintide在慢性管理中促进负能量平衡的潜力的洞察力.

关键词:

艾米林氨基酸是什么?糖尿病糖尿病糖尿病饮食模式饮食模式肥胖问题肥胖问题普拉姆林提德是什么意思和度 (Satiation) 是一种满足度.

更多相关视频

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Self-Administration of Drugs in Mouse Models of Feeding and Obesity

Published on: June 8, 2021

Manipulation of Rhythmic Food Intake in Mice Using a Custom-Made Feeding System

Manipulation of Rhythmic Food Intake in Mice Using a Custom-Made Feeding System

Published on: December 16, 2022

相关概念视频

Regulation of Food Intake

Regulation of Food Intake

Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...

Glucagon-like Receptor Agonists

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...